Press Room
News & Events
 
April 28, 2014
Phase I Clinical Study of Neumedicines' Interleukin-12 as a Treatment for Wound Healing and Infections Recommended for Funding by the U.S. Department of Defense

 
April 18, 2014
Neumedicines Publishes Clinical Data Demonstrating Safety and Hematopoietic and Immune Effects of HemaMax™ (rHuIL-12), a Radiation Medical Countermeasure

 
April 15, 2014
Neumedicines Announces Publication of Phase II-Equivalent Data Demonstrating the Survival Effect of HemaMax™ (rHuIL-12), a Radiation Medical Countermeasure

 
Jan 9, 2014
Neumedicines to Feature HemaMax Study Results in Presentation at Biotech Showcase Conference

 
Jan 8, 2014
Neumedicines' Study Shows HemaMax, Not Neupogen (G-CSF), Improves Survival Outcomes Following Lethal Irradiation

 
Jan 2, 2014
Neumedicines Joins the Alliance for Biosecurity

 
June 10, 2013
Neumedicines Receives an Award of $8.3 Million from BARDA for Continued Development of HemaMax as a Countermeasure to Acute Radiation Exposure

 
May 14, 2013
Neumedicines Receives BARDA Notification of Intent to Exercise Contract Option to Continue Development of HemaMax as Radiation Medical Countermeasure

 
March 6, 2013
Neumedicines Names Financial Veteran David L. Morash Chief Financial Officer and Director

 
Jan 25, 2013
Neumedicines Presents at BARDA and NIAID Sponsored Symposium onDevelopment of Radiation Medical Countermeasures for Licensure

 
March 5, 2012
Neumedicines’ Anti-Radiation Therapy (HemaMax™) Demonstrates Unprecedented Survivability After Lethal Dose of Radiation in Mice an Non-human Primates

 
Dec 18, 2012
Neumedicines Phase 1b Study Shows HemaMax™ is Safe and Well-Tolerated at aHuman Dose Equivalent to an Efficacious Dose in Non-human Primates

 
Dec 1, 2012
Neumedicines’ HemaMax™ Proves Efficacious in a GLP, Blinded, Non-humanPrimate Study in Acute Radiation Syndrome

 
Oct 1, 2012
Neumedicines Presents at the 58th Annual Radiation Research Society Meeting

 
Sept 1, 2012
Neumedicines Receives $8.8 Million in BARDA Funding for Second SupportiveSpecies Studies in Mice to Support the Development of HemaMax™ for HSARS

 
Sept 26, 2011
Neumedicines Wins U.S. Federal Government Contract for up to $273 Million to Fund Late-Stage Development of HemaMax(TM), a Novel Radiation Medical Countermeasure

 
June 8, 2011
Neumedicines Initiates Dosing in a First-in-Human Study of HemaMax™, its Novel Radiation Medical Countermeasure

 
June 6, 2011
Neumedicines’ Oncology and Hematology Drug Candidates Featured in BIOWORLD Magazine

 
Jan 27, 2011
Neumedicines Receives Notice of Allowance for Patent Covering Use of HemaMax™ (rHuIL-12) to Treat Chemotherapy-Induced Thrombocytopenia (CIT)

 
Jan 5, 2011
Neumedicines to Present at the 2011 Biotech Showcase™ Tuesday, January 11, 2011

 
Aug 12, 2010
Neumedicines Receives $2.5 Million from HHS/BARDA After Successful Non-Human Primate Studies to Further Advance HemaMax™ as a Radiation Countermeasure

 
Oct 1, 2009
Neumedicines Receives Approximately $5 Million from HHS/BARDA in Research and Development Funding

 
Sept 16, 2008
Neumedicines Awarded BAA-BARDA-08-08 Contract by the Biomedical Research and Development Authority (BARDA)

Neumedicines in the News
 
Date
Title

 
May 2, 2012
"Biotech Focus On Radiation Threat Could Help Cancer Patients Too," WSJ.com

 
Jun 6, 2011
"Neumedicines Gives New Life to Failed Biologic," BioWorld Today

 
April 19, 2011
"Japan Serves as Textbook for BARDA and Biotechs," BioWorld Today

 
Dec 12, 2009
"Bringing New Blood to the Anemia Market," Start-Up Magazine

 
Dec 1, 2009
"Start-Up Previews," IN VIVO Magazine

Follow Us @Neumedicines
Corporate news, events and interests